Trial Profile
RATinG (Risk Adapted Therapy in acute GvHD): investigating the use of lenzilumab for treating high-risk acute graft versus host disease following allogeneic stem cell transplantation
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 17 Mar 2023
Price :
$35
*
At a glance
- Drugs Lenzilumab (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms RATinG
- Sponsors Humanigen
- 05 May 2022 Accoding to a Humanigen media release, University of Birmingham, UK notified that amended Investigational Medicinal Product Dossier has been accepted by Medicines & Healthcare products Regulatory Agency for this study. The company enrolled first patient in the second quarter.
- 08 Feb 2022 Status changed from planning to recruiting.
- 11 Nov 2021 Accoding to a Humanigen media release, If an independent data monitoring committee deem the second stage to be feasible, then the trial will progress to its double-blind, randomized (1:1), second stage, which will enroll a minimum of 220 patients. A second interim analysis is planned to assess futility based upon the 28-day response rate to the first infusion in the first 150 evaluable patients.